Therapy for Advanced NSCLC With EGFR 19delins Mutation
NCT07458919
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
94
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Icotinib/Gefitinib
Sponsor
Fuzhou General Hospital